Fossati, Andrea http://orcid.org/0000-0001-5170-4903
Mozumdar, Deepto
Kokontis, Claire
Mèndez-Moran, Melissa http://orcid.org/0000-0003-0817-7292
Nieweglowska, Eliza http://orcid.org/0000-0002-9204-3002
Pelin, Adrian
Li, Yuping http://orcid.org/0000-0003-2057-3271
Guo, Baron
Krogan, Nevan J. http://orcid.org/0000-0003-4902-337X
Agard, David A. http://orcid.org/0000-0003-3512-695X
Bondy-Denomy, Joseph http://orcid.org/0000-0002-4909-9481
Swaney, Danielle L. http://orcid.org/0000-0001-6119-6084
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R01AI167412, 1F32GM149125-01, 1R01AI167412)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 13 March 2023
Accepted: 7 August 2023
First Online: 24 August 2023
Competing interests
: The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche, and Rezo Therapeutics. Nevan Krogan has previously held financially compensated consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, and Twist Bioscience Corp. He currently has financially compensated consulting agreements with Maze Therapeutics, Interline Therapeutics, Rezo Therapeutics, and GEn1E Lifesciences, Inc. He is on the Board of Directors of Rezo Therapeutics and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, and Interline Therapeutics. D.L.S. has financially compensated consulting agreements with Maze Therapeutics and Rezo Therapeutics. The other authors declare no competing interests